EP1056762A4 - Immunisation genetique avec des proteines non structurales du virus de l'hepatite c - Google Patents

Immunisation genetique avec des proteines non structurales du virus de l'hepatite c

Info

Publication number
EP1056762A4
EP1056762A4 EP99904381A EP99904381A EP1056762A4 EP 1056762 A4 EP1056762 A4 EP 1056762A4 EP 99904381 A EP99904381 A EP 99904381A EP 99904381 A EP99904381 A EP 99904381A EP 1056762 A4 EP1056762 A4 EP 1056762A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
virus
nonstructural proteins
genetic immunization
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99904381A
Other languages
German (de)
English (en)
Other versions
EP1056762A1 (fr
Inventor
Jack Wands
Jens Encke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1056762A1 publication Critical patent/EP1056762A1/fr
Publication of EP1056762A4 publication Critical patent/EP1056762A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP99904381A 1998-01-30 1999-01-28 Immunisation genetique avec des proteines non structurales du virus de l'hepatite c Withdrawn EP1056762A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7315698P 1998-01-30 1998-01-30
US73156P 1998-01-30
PCT/US1999/001823 WO1999038880A1 (fr) 1998-01-30 1999-01-28 Immunisation genetique avec des proteines non structurales du virus de l'hepatite c

Publications (2)

Publication Number Publication Date
EP1056762A1 EP1056762A1 (fr) 2000-12-06
EP1056762A4 true EP1056762A4 (fr) 2003-07-23

Family

ID=22112053

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99904381A Withdrawn EP1056762A4 (fr) 1998-01-30 1999-01-28 Immunisation genetique avec des proteines non structurales du virus de l'hepatite c

Country Status (9)

Country Link
EP (1) EP1056762A4 (fr)
JP (1) JP2002501737A (fr)
KR (2) KR20060057653A (fr)
CN (3) CN101126095A (fr)
AU (1) AU746258B2 (fr)
BR (1) BR9908540A (fr)
CA (1) CA2318744A1 (fr)
IL (1) IL137458A0 (fr)
WO (1) WO1999038880A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1232267B1 (fr) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation de lymphocytes t specifiques au virus de l'hepatite c
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
CA2461380C (fr) 2001-10-11 2011-03-22 Merck & Co., Inc. Vaccin contre le virus de l'hepatite c
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
KR101679731B1 (ko) * 2011-10-24 2016-11-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037606A1 (fr) * 1995-05-22 1996-11-28 Bionova Corporation Procedes et compositions de diagnostic d'infections par le virus de l'hepatite c et de vaccination contre le virus de l'hepatite c
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1997047358A1 (fr) * 1996-06-11 1997-12-18 Merck & Co., Inc. Genes synthetiques de l'hepatite c
WO1999029843A1 (fr) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Proteine tronquee du virus ns5b de l'hepatite c et procedes associes d'identification de composes antiviraux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079105C (fr) * 1990-04-04 2000-06-13 Michael Houghton Protease du virus de l'hepatite c
WO1994016737A1 (fr) * 1993-01-26 1994-08-04 Weiner David B Compositions et procedes d'administration de matieres genetiques
EP0935662B1 (fr) * 1996-05-24 2005-11-30 Chiron Corporation Proteine de fusion a epitopes multiples

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1996037606A1 (fr) * 1995-05-22 1996-11-28 Bionova Corporation Procedes et compositions de diagnostic d'infections par le virus de l'hepatite c et de vaccination contre le virus de l'hepatite c
WO1997047358A1 (fr) * 1996-06-11 1997-12-18 Merck & Co., Inc. Genes synthetiques de l'hepatite c
WO1999029843A1 (fr) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Proteine tronquee du virus ns5b de l'hepatite c et procedes associes d'identification de composes antiviraux

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHOO Q-L ET AL: "GENETIC ORGANIZATION AND DIVERSITY OF THE HEPATITIS C VIRUS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, 1 March 1991 (1991-03-01), pages 2451 - 2455, XP000652139, ISSN: 0027-8424 *
ENCKE J. ET AL.: "Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model", JOURNAL OF IMMUNOLOGY, vol. 161, no. 9, 1 November 1998 (1998-11-01), pages 4917 - 4923, XP002233910 *
INCHAUSPE G.: "Gene vaccination for hepatitis C", SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 19, no. 2, 1997, pages 211 - 221, XP008014824 *
INCHAUSPE G.: "Mechanism of protection in hepatitis C virus infection", MEDECINE ET MALADIES INFECTIEUSES, vol. 25, October 1995 (1995-10-01), pages 1067 - 1073, XP008017646 *
PAPA S. ET AL.: "Development of a multigenic plasmid vector for HCV DNA immunization", RESEARCH IN VIROLOGY, vol. 149, no. 5, September 1998 (1998-09-01), pages 315 - 319, XP002233911 *
SAITO T ET AL: "PLASMID DNA-BASED IMMUNIZATON FOR HEPATITIS C VIRUS STRUCTURAL PROTEINS: IMMUNE RESPONSES IN MICE", GASTROENTEROLOGY, vol. 112, no. 4, April 1997 (1997-04-01), pages 1321 - 1330, XP001013414, ISSN: 0016-5085 *
See also references of WO9938880A1 *
STUYVER L ET AL: "CLONING AND PHYLOGENETIC ANALYSIS OF THE CORE, E2, AND NS3/NS4 REGIONS OF THE HEPATITIS C VIRUS TYPE 5A+", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 202, no. 3, 1994, pages 1308 - 1314, XP002057873, ISSN: 0006-291X *

Also Published As

Publication number Publication date
BR9908540A (pt) 2000-11-28
AU746258B2 (en) 2002-04-18
CN101126094A (zh) 2008-02-20
KR100628411B1 (ko) 2006-09-28
KR20060057653A (ko) 2006-05-26
EP1056762A1 (fr) 2000-12-06
CN100335637C (zh) 2007-09-05
JP2002501737A (ja) 2002-01-22
CA2318744A1 (fr) 1999-08-05
IL137458A0 (en) 2001-07-24
CN1289339A (zh) 2001-03-28
CN101126095A (zh) 2008-02-20
KR20010086226A (ko) 2001-09-10
WO1999038880A1 (fr) 1999-08-05
AU2478699A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
PL324906A1 (en) Vaccines against viral hepatitis of c type
ZA981838B (en) Functional DNA clone for hepatitis C virus (HCV) and uses thereof
DE60014345D1 (en) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
DK1001801T3 (da) Produkt omfattende mindst en dobbeltkædet RNA kombineret med mindst et interferon til behandling af viral hepatitis
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
ZA9811316B (en) Novel hepatitis C virus NS5B protein
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
EP1627917A4 (fr) Construit d'acide nucleique contenant le virus de l'hepatite c (v h c) de l'acide nucleique d'origine du genome de genotype 2a et des cellules possedant ce construit d'acide nucleique transfere dans celles-ci
ZA985762B (en) Screening methods using an atpase protein from a virus of the flaviviridae family
AU3714499A (en) Hepatitis c virus mimotopes
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
HK1062579A1 (en) A fusion protein for treatment of hepatitis b virus and its use thereof
EP1141255A4 (fr) Formes modifiees de la protease ns3 du virus de l'hepatite c
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
EP0747482A3 (fr) Protéines récombinantes de virus de l'hépatite GB et leur utilisations
IL137458A0 (en) Genetic immunization with nonstructural proteins of hepatitis c virus
EP1100545A4 (fr) Expression regulee de proteines recombinantes au moyen de virus a arn
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
EP1113777A4 (fr) Nouveaux peptides du virus de l'hepatite c et utilisations de ceux-ci
AU9494998A (en) (in vivo), animal model for expression of hepatitis c virus
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
EP1521849A4 (fr) Sequences nucleotidiques du virus de l'hepatite a, proteines recombinantes et utilisations associees
AU5681598A (en) Liposomes comprising peptide antigens derived from x protein of hepatitis b virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/18 B

Ipc: 7A 61K 39/29 B

Ipc: 7A 61K 39/12 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 12N 15/51 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07H 21/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030604

17Q First examination report despatched

Effective date: 20040824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080602